JUN 20, 2019 10:30 AM PDT

Beyond the Score: Tools for Pan-Biomarker Analysis and TMB Estimation Enabling Deeper Understanding of Somatic Alterations that Contribute to Cancer Initiation, Progression and Recurrence

SPONSORED BY: QIAGEN
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Product Owner of QIAGEN Clinical Insight (QCI™) Intepret
    Biography
      Dr. Beate Litzenburger is the product owner of QIAGEN Clinical Insight (QCI™) Intepret. Prior to joining the QIAGEN team, Dr. Litzenburger led clinical decision support for several next generation sequencing research protocols at MD Anderson Cancer Center. In this role, Dr. Litzenburger was responsible for providing alteration interpretation, drug, and clinical trial options to clinicians. Dr. Litzenburger received her Ph.D. in molecular genetics from the University of Aachen in Germany and was a National Cancer Institute-supported post-doctoral fellow in the Department of Clinical Cancer Prevention at MD Anderson Cancer Center.
    • Senior Global Product Manager, QIAGEN
      Biography
        Raed Samara, PhD is a Global Product Manager for NGS technologies at QIAGEN, with a focus on pre-analytics and targeted enrichment. Prior to joining QIAGEN, he was a postdoctoral fellow at the National Cancer Institute conducting research in the field of cancer immunology with emphasis on identifying strategies to boost the efficacy of cancer vaccines. He received his Ph.D. degree from Georgetown University in tumor biology.

      Abstract:

      Tumor mutational burden (TMB) is an emerging biomarker that correlates with response to immunotherapeutic agents, such as checkpoint inhibitors. Recent studies indicate that a high mutation load increases the likelihood that immunogenic neoantigens expressed by tumor cells may induce a response to immunotherapy.  However, TMB estimation and reporting can be heavily influenced by differing working processes across clinical and research laboratories; primarily, the choice of assay, platform, and how the assay is implemented and interpreted. 

      In the first half of the webinar, we introduce the QIAseq Tumor Mutational Burden (TMB) Panel, a comprehensive next-generation sequencing (NGS) assay that targets the full coding region of 486 genes implicated in the pathogenesis of solid tumors and can be boosted to add 27 microsatellite instability (MSI) markers. From optimized primer design based on the robust UMI-enabled single primer extension (SPE) chemistry, which reduces false positives and eliminates duplicate reads, and now coupled with the CLC Genomics Workbench, the QIAseq Tumor Mutation Burden Panel ensures TMB estimation consistent with best practices as reported by the Friends of Cancer Research (Genes, Chromosomes & Cancer, 2019). With QIAGEN Clinical Insight (QCI™) – Interpret, insights for variants detected, based on private and publicly available data sources, are provided, enabling a better understanding of these variants and their role in tumor initiation, growth, spread and recurrence.

      In the second half we present a scalable bioinformatics solution for the interpretation of somatic mutations. Cancer laboratories need rapid and reliable interpretation of identified genomic alterations. One of the challenges they face is producing standardized, reproducible interpretation and reporting of the most current and actionable information. QIAGEN Clinical Insight (QCI™) Interpret enables labs to deliver evidence-based, actionable insights and reporting of variants and TMB and MSI scores from tumor genomic profiles. We will discuss the benefits of automating guidelines (AMP/ASCO/CAP and ACMG/AMP) for vetting somatic cancer alterations for biological and actionable relevance while providing the evidence behind each automated classification via direct links to the source, facilitating insights that improve clinical trial matching.

      Learning Objectives: 

      1. Learn how the coupled solution of UMI-enabled single primer extension (SPE) and the well renowned CLC algorithms for secondary analysis enables the coverage and high confidence detection of variants, even those at low frequency (as low as 0.4%) while minimizing impact of PCR duplicates and false positives which could inflate TMB scores
      2. Learn how the QIAGEN Clinical Insight (QCI™)- Interpret clinical decision support platform can enable rapid and consistent reporting of variant pathogenicity and actionability, resulting in better clinical trial matching.


      Show Resources
      You May Also Like
      FEB 26, 2019 09:00 AM PST
      C.E. CREDITS
      FEB 26, 2019 09:00 AM PST
      DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
      MAY 16, 2019 04:00 PM CEST
      C.E. CREDITS
      MAY 16, 2019 04:00 PM CEST
      DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
      JUN 05, 2019 05:00 PM CEST
      C.E. CREDITS
      JUN 05, 2019 05:00 PM CEST
      DATE: June 5, 2019TIME: 8:00am PDT, 11:00am EDT, 5:00pm CEST Eukaryotic cell cultures respond to the most subtle influence. Apart from the risk of contamination, minimal chan...
      MAR 26, 2019 02:00 PM PDT
      C.E. CREDITS
      MAR 26, 2019 02:00 PM PDT
      DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
      FEB 27, 2019 08:00 AM PST
      C.E. CREDITS
      FEB 27, 2019 08:00 AM PST
      DATE:  February 27, 2019TIME:  8:00am PST Pluripotent stem cells (PSCs) can form any tissue or cell in the body, and are the ideal starting material to manufacture...
      JUN 19, 2019 10:00 AM PDT
      JUN 19, 2019 10:00 AM PDT
      DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
      Loading Comments...
      Show Resources